Dataset Information

Memantine administration enhances glutamatergic and GABAergic pathways in human hippocampus of Alzeimer´s disease patients

ABSTRACT: Alzheimer´s disease (AD) represents a serious health, social and economic problem. One of the traditional treatment is administration of memantine, the NMDA receptor antagonist. In this study we investigated how memantine medication impacts protein expression in hippocampus of AD patients using TMT-based quantitative proteomics applied on formalin-fixed paraffin embedded post mortem tissues. The presented dataset shows that memantine treatment has minor but distinct effect on protein expression. While memantine did not prevented general decline of mitochondrial proteome seen in unmedicated AD patients, the treatment selectively induced levels of several mitochondrially-encoded proteins. Furthermore, memantine medication mitigated proteomic pattern of activated phagocytes and enhanced expression of synaptic components involved in both inhibitory (GABA) and excitatory (glutamate) neurotransmission. The upregulation was specific for proteins for which glutamate/GABA serves as a ligand or a substrate (i.e. receptors, transporters, enzymes, etc.), without affecting neuronal nor post-synaptic density markers. This may indicate that memantine-associated effects on glutamatergic and GABAergic is a reaction to memantine-mediated changes of glutamate and GABA levels.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Hippocampus

DISEASE(S): Alzheimer's Disease

SUBMITTER: Ivo Fabrik

LAB HEAD: Ondrej Soukup

PROVIDER: PXD052958 | Pride | 2026-02-09

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	FragPipe_output.zip	Other
	RK114_IF232_2D_TMT_0p8ug_M1_A_01.raw	Raw
	RK114_IF232_2D_TMT_0p8ug_M1_A_02.raw	Raw
	RK114_IF232_2D_TMT_0p8ug_M1_B_01.raw	Raw
	RK114_IF232_2D_TMT_0p8ug_M1_B_02.raw	Raw

Items per page:

1 - 5 of 196

Publications

Memantine Administration Enhances Glutamatergic and GABAergic Pathways in the Human Hippocampus of Alzheimer's Disease Patients.

Fabrik Ivo I Kupcik Rudolf R Fabrikova Daniela D Chvojkova Marketa M Holubova Kristina K Hakenova Kristina K Horak Martin M Soukup Jiri J Manethova Monika M Rusina Robert R Matej Radoslav R Ryska Ales A Soukup Ondrej O

Proteomics 20250709 15

One of the traditional treatments in Alzheimer's disease (AD) is administration of memantine, the NMDA receptor antagonist. However, the molecular mechanism of the complex memantine action and the impact on the hippocampal proteome in humans is unknown. In this study, hippocampal proteins extracted from formalin-fixed paraffin-embedded post mortem tissues obtained from healthy donors (n = 15), AD patients not treated with memantine (n = 11), and AD patients treated with memantine (n = 8) were in ...[more]

PMID: 40879647

Similar Datasets

Project description:Background: Of the many neurotransmitters in humans, gamma-aminobutyric acid (GABA) shows potential for improving several mental health indications such as stress and anxiety. The microbiota-gut-brain axis is an important pathway for GABAergic effects, as microbially-secreted GABA within the gut can affect host mental functionhealth outcomes. Understanding the molecular characteristics of GABA production by microbes within the gut can offer insight to novel therapies for mental health. Results: Three strains of Levilactobacillus brevis with syntenous glutamate decarboxylase (GAD) operons were evaluated for overall growth, glutamate utilization, and GABA production in typical synthetic growth media supplemented with monosodium glutamate (MSG). Levilactobacillus brevis Lbr-6108 (Lbr-6108) and Levilactobacillus brevis Lbr-35 (Lbr-35) had similar growth profiles but differed significantly in GABA secretion and acid resistance. Lbr-6108 produced GABA early, within the growth phase, and produced significantly more GABA than Lbr-35 and the type strain Levilactobacillus brevis ATCC 14689 after the stationary phase. The global gene expression during GABA production was determined by RNA sequencing at several timepoints. The GAD operon, responsible for GABA production and secretion, activated in Lbr-6108 after only six hours of fermentation and continued throughout the stationary phase. Furthermore, Lbr-6108 activated many different acid resistance mechanisms concurrently, which contribute to acid tolerance and energy production. In contrast, Lbr-35, which has a genetically similar GAD operon, including two copies of the GAD gene, showed no upregulation of the GAD operon, even when cultured with MSG. Conclusions: This study is the first to evaluate whole transcriptome changes in L. brevis during GABA production over multiple timepoints. The concurrent expression of multiple acid-resistance mechanisms reveals niche-specific metabolic functionality between common human commensals and highlights the complex regulation of GABA metabolism in this important microbial species. Furthermore, the increased and rapid GABA production of Lbr-6108 highlights the strain’s potential as a therapeutic and the overall value of screening microbes for effector molecule output.

Project description:The rostral ventrolateral medulla (RVLM), a part of the medullary reticular formation, plays a major role in several physiological responses, including cardiovascular and sympathetic nervous system functions. Although aging causes disturbances in the responses of these physiological systems, RVLM involvement in these age-related changes is not clear. Previous work using high-throughput gene expression analysis of the RVLM in aged animals suggested that chemical neurotransmission-related genes might be downregulated with advancing age. Since the RVLM function involves a balance of inhibitory and excitatory inputs, which is largely mediated by gamma-aminobutyric acid (GABA) and excitatory amino acid (EAA) neurotransmission, we hypothesized that aging is associated with altered excitatory and/or inhibitory neurotransmission-related gene expression in the RVLM. To test this hypothesis, we micropunched an RVLM-containing area from young (3–5 months), middle-aged (12–14 months), and aged (22–26 months) Fischer 344 male rats. RNA purified from these micropunches was analyzed using GABA and Glutamate RT2 Profiler PCR arrays (n= 8–10). In addition, the expression of selected genes was validated at the RNA level using TaqMan® based- qPCR and at the protein level using western blotting. All the genes that displayed significant differential expression (1.5-fold, p < .05, FDR < .05) were identified to be downregulated in the RVLM of aged and middle-aged rats compared to young rats. Among the downregulated genes, the percentage of glutamate neurotransmission-related genes was higher than GABA neurotransmission-related genes. Solute carrier family 1 member 6 (Slc1a6) gene showed the highest fold downregulation at the RNA level in the RVLM of aged compared to young rats, and its protein product, Excitatory amino acid transporter 4 (EAAT4), showed a downregulatory trend in the RVLM of aged and middle-aged rats. These results suggest that molecular constituents of both GABA and glutamate neurotransmission might be altered in the RVLM of aged and middle-aged rats, and the changes in glutamate neurotransmission might be more prominent. Investigating age-associated anatomical and functional changes in RVLM GABA and glutamate neurotransmission might provide a foundation for understanding the effects of aging on physiological function.